Compare AVT & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVT | APGE |
|---|---|---|
| Founded | 1921 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 4.7B |
| IPO Year | 1994 | 2023 |
| Metric | AVT | APGE |
|---|---|---|
| Price | $80.80 | $82.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $59.33 | ★ $109.67 |
| AVG Volume (30 Days) | ★ 1.2M | 577.3K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.36 | N/A |
| Revenue | ★ $22,200,754,000.00 | N/A |
| Revenue This Year | $14.39 | N/A |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | $60.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $44.25 | $34.34 |
| 52 Week High | $84.07 | $95.32 |
| Indicator | AVT | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 74.42 | 47.43 |
| Support Level | $58.49 | $73.06 |
| Resistance Level | N/A | $84.56 |
| Average True Range (ATR) | 2.32 | 3.38 |
| MACD | 0.62 | -1.34 |
| Stochastic Oscillator | 78.43 | 15.56 |
Avnet Inc is an electronic component technology distributor and solutions provider. It serves customers from startups and mid-sized businesses to enterprise-level original equipment manufacturers (OEMs), electronic manufacturing services (EMS) providers, and original design manufacturers (ODMs). The group operates in the Electronic Components segment and supports high and medium-volume customers to markets, sells, and distributes electronic components, and the Farnell segment supports lower-volume customers that need electronic components quickly to develop, prototype, and test their products. Its geographic regions are the Americas, EMEA, and Asia.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.